Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences
For Journalists
Manager
Telephone: 412-586-9773
Senior Director
Telephone: 412-586-9777
For Patients and Non-Media
Want to make an appointment or need patient info?



New Study Shows Targeted Therapy Needed for Breast Cancer with Brain Metastases

PITTSBURGH, Dec. 7, 2016 – Researchers at the University of Pittsburgh Cancer Institute (UPCI) and Magee-Womens Research Institute (MWRI) have discovered molecular changes in the primary tumor of breast cancer patients who developed brain metastases. The finding is expected to lead to improved diagnosis and targeted therapies. 
 
The results, to be published in the Journal of the American Medical Association (JAMA) Oncology and presented this week at the 2016 San Antonio Breast Cancer Symposium, indicate that patients’ treatments should be tailored not only for the original breast cancer, but also the brain tumors, said Adrian Lee, Ph.D., director of the Institute for Precision Medicine, a joint effort by UPMC and the University of Pittsburgh, and director of the Women’s Cancer Research Center, a collaboration between UPCI and MWRI.
 
“The brain is a common and catastrophic site of metastasis for breast cancer patients,” said Lee. “Our study showed that despite the large degree of similarity between the initial breast tumor and the brain metastatic tumor, there were enough alterations to support comprehensive profiling of metastases to potentially alter the course of treatment.”
 
There are many types of breast cancers, and about 20 percent of them are identified as HER2-positive, meaning the cancer cells have more of a protein called HER2 that causes the cells to grow faster than those with normal levels of the protein. These patients’ cancers typically respond to targeted therapies. However, breast cancer patients with brain metastases who are identified as HER2-negative do not respond favorably to the same therapies.
 
Lee’s research team set out to determine if there were molecular differences in the primary breast tumors and their patient-matched brain metastatic tumors that would enhance treatment options.
 
Little research is available because there are few opportunities to study primary breast tissue with their patient-matched brain metastases. The research team tested tumors from 20 patients from two academic institutions, the University of Pittsburgh and the Royal College of Surgeons in Ireland. Among the discoveries was that the primary tumor initially identified as HER2-negative actually switched to HER2-positive in the metastatic brain tumor.
 
“This now means we can screen for presence of HER2 so that we can change and target the therapy to improve outcomes for our patients,” said Dr. Lee.
 
Additional authors on this study are Nolan Priedigkeit, B.S., Yijing Chen, B.S., Ahmed Basudan, B.S., Rebecca J. Watters, Ph.D., Roby Thomas, M.D., Peter C. Lucas, M.D., Ph.D., Rohit Bhargava, M.D., Ronald L. Hamilton, M.D., Shannon L. Puhalla, M.D., Nancy E. Davidson, M.D., Steffi Oesterreich, Ph.D., and Adam M. Brufsky, M.D., Ph.D.,  all of UPCI; Ryan J. Hartmaier, Ph.D., and Juliann Chmielecki, Ph.D., both of the Foundation Medicine, Cambridge, Massachusetts; Damir Vareslija, Ph.D., and Leonie Young, Ph.D., both of the Royal College of Surgeons in Ireland; and Jose P. Leone, M.D., of the University of Iowa.
 
This research was supported by the Breast Cancer Research Foundation, National Cancer Institute grant P30CA047904, Fashion Footwear Association of New York, the Shear Family Foundation, Magee-Womens Research Institute and Foundation, Susan G. Komen for the Cure, National Institute of General Medical Sciences grants 2T32GM008424-21 and 5F30CA203095, and the Irish Cancer Society Collaborative Cancer Research Centre grant CCRC13GAL.
 
Several of the authors disclosed conflicts of interest, which can be viewed on the JAMA Oncology publication.

UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences Supplemental content provided by Healthwise, Incorporated. To learn more, visit www.healthwise.org

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, gender identity, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

UPMC
Pittsburgh, PA, USA | UPMC.com